# Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

> **NCT06161558** · PHASE1 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Lenvatinib
- **DRUG:** Axitinib

## Key facts

- **NCT ID:** NCT06161558
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-07-15
- **Primary completion:** 2025-07-15
- **Final completion:** 2025-07-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of resources to complete study objectives. No participants enrolled.
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06161558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06161558, "Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06161558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*